The NME3 antibody is designed to target the NME/NM23 nucleoside diphosphate kinase 3. a member of the NME/NM23 family of proteins implicated in cellular processes such as nucleotide metabolism, cytoskeletal dynamics, and metastasis suppression. NME3. also known as NM23-H3. shares structural homology with other family members, featuring conserved nucleoside diphosphate kinase (NDPK) domains critical for its enzymatic activity in ATP synthesis and GTP regeneration. Unlike its well-studied relatives NME1 and NME2. NME3 localizes predominantly to mitochondria and interacts with proteins involved in mitochondrial fusion (e.g., MFN1/2) and apoptosis regulation, suggesting a role in mitochondrial homeostasis and stress responses.
NME3 antibodies are utilized in research to investigate its dual functions: as a kinase regulating energy metabolism and as a potential tumor suppressor or promoter, depending on cellular context. Studies link NME3 to cancer progression, neurodegenerative diseases, and cardiovascular disorders, often through its interaction with p53 or modulation of oxidative stress pathways. Its antibody aids in detecting protein expression levels, subcellular localization, and post-translational modifications in experimental models, providing insights into disease mechanisms. However, conflicting reports on its pro- or anti-metastatic roles underscore the need for further exploration. Commercial NME3 antibodies are validated for applications like Western blot, immunofluorescence, and immunohistochemistry, supporting both basic research and clinical biomarker studies.